Predictive Findings of Visual Outcome in Spectral Domain Optical Coherence Tomography after Ranibizumab Treatment in Age-related Macular Degeneration.
10.3341/kjo.2014.28.5.386
- Author:
Yoon Hyung KWON
1
;
Dong Kyu LEE
;
Hyung Eun KIM
;
Oh Woong KWON
Author Information
1. Department of Ophthalmology, Dong-A University College of Medicine, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Choroidal neovascularization;
Macular degeneration;
Optical coherence tomography
- MeSH:
Aged;
Aged, 80 and over;
Angiogenesis Inhibitors/*therapeutic use;
Choroidal Neovascularization/*drug therapy/physiopathology;
Female;
Humans;
Intravitreal Injections;
Male;
Middle Aged;
Ranibizumab/*therapeutic use;
Retinal Photoreceptor Cell Inner Segment/pathology;
Retinal Photoreceptor Cell Outer Segment/pathology;
Tomography, Optical Coherence;
Vascular Endothelial Growth Factor A/antagonists & inhibitors;
Visual Acuity/*physiology;
Wet Macular Degeneration/*drug therapy/physiopathology
- From:Korean Journal of Ophthalmology
2014;28(5):386-392
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To investigate which spectral domain optical coherence tomography (SD-OCT) findings predict visual outcome after anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (NV-AMD). METHODS: We reviewed the medical records of patients with treatment-naive NV-AMD who underwent three or more consecutive anti-VEGF injections. The patients were divided into three groups according to their changes of visual acuity (VA); improved (group I), static (group S), or worsened (group W). We assessed the incidences and values of all available SD-OCT findings of these groups, compared these findings between the three groups and compared the initial values with the post-treatment values. RESULTS: Better initial VA and longer external limiting membrane (ELM) length were associated with less change in VA after anti-VEGF treatment. The initial VA was mildly correlated with initial photoreceptor inner and outer segment junction (IS/OS) length and initial ELM length. The final VA was also mildly correlated with the final IS/OS length and the final ELM length. VA was significantly changed after anti-VEGF treatment in groups W and I. With regard to incidence, disruption of the IS/OS (IS/OS-D), disruption of the ELM (ELM-D) and ELM length differed significantly between the three groups, particularly ELM-D. The incidences of IS/OS-D and ELM-D in group I were significantly lower than those in groups S and W, and those in group S were also lower than those in group W. The ELM length in group I was significantly longer than it was in groups S and W, and the ELM length in group S was longer than that for group W. However, these three findings did not change after the anti-VEGF treatment. CONCLUSIONS: Initial IS/OS-D, ELM length and particularly ELM-D can be useful predictors of the visual outcome after anti-VEGF treatment in NV-AMD patients.
